Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 122,000 shares, an increase of 60.7% from the February 28th total of 75,900 shares. Based on an average daily trading volume, of 89,000 shares, the short-interest ratio is currently 1.4 days. Approximately 0.2% of the shares of the company are sold short.

Alpha Tau Medical Stock Performance

DRTS stock traded up $0.08 during trading on Wednesday, reaching $2.58. 36,773 shares of the company were exchanged, compared to its average volume of 48,822. The stock's 50 day moving average price is $2.99 and its 200 day moving average price is $2.81. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $4.39. The company has a market cap of $181.58 million, a P/E ratio of -6.00 and a beta of 0.87.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). As a group, equities research analysts forecast that Alpha Tau Medical will post -0.45 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Alpha Tau Medical in a research note on Monday, March 17th.

Institutional Investors Weigh In On Alpha Tau Medical

A number of large investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. lifted its holdings in shares of Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock valued at $975,000 after purchasing an additional 7,189 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Alpha Tau Medical by 112.6% in the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after acquiring an additional 25,770 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after acquiring an additional 26,800 shares in the last quarter. 2.65% of the stock is owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.